scholarly journals Metronomic chemotherapy of cyclophosphamide plus methotrexate for advanced breast cancer: Real‐world data analyses and experience of one center

2020 ◽  
Vol 40 (5) ◽  
pp. 222-233 ◽  
Author(s):  
Qianyi Lu ◽  
Kaping Lee ◽  
Fei Xu ◽  
Wen Xia ◽  
Qiufan Zheng ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Real World ◽  
Metronomic Chemotherapy ◽  
Advanced Breast ◽  
Real World Data ◽  
World Data ◽  
Data Analyses

REAL WORLD DATA OF CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN A EUROPEAN AND LATIN-AMERICAN LUMINAL ADVANCED BREAST CANCER POPULATION. ANALYSIS OF TWO CENTERS

The Breast ◽  
2019 ◽  
Vol 48 ◽  
pp. S55
Author(s):  
Juan Carlos Samamé Pérez-Vargas ◽  
Ariadna Gasol Cudós ◽  
Victor Mauricio Rivera Francia ◽  
Alejandro León Garrido-Lecca ◽  
Silvia Falcón Lizaraso ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Latin American ◽  
Real World ◽  
Population Analysis ◽  
Advanced Breast ◽  
Cyclin Dependent Kinase ◽  
Real World Data ◽  
World Data

CDK4/6 inhibitors and hormone therapy in hormone receptor-positive advanced breast cancer: Real-world data and intrinsic subtypes defined by PAM50.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e13035-e13035
Author(s):  
Tamara Diaz Redondo ◽  
Rocío Lavado-Valenzuela ◽  
Maria Emilia Dominguez-Recio ◽  
Sofía Ruíz ◽  
Encarnación González Flores ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
Advanced Breast Cancer ◽  
Hormone Therapy ◽  
Real World ◽  
Hormone Receptor ◽  
Advanced Breast ◽  
Real World Data ◽  
World Data ◽  
Hormone Receptor Positive

e13035 Background: CDK 4/6 inhibitors plus hormone therapy(HT) has been approved by FDA and EMA for the treatment of hormone receptor positive HER2 negative advanced breast cancer (HR+/HER2-BC) with improvement in PFS consistently demonstrated in several clinical trials. Benefit in OS has also been demonstrated in Monaleesa3 and Monarch2 clinical trials. To date we don`t have real-world data and no single biomarker has been validated to identify subgroups that would benefit most from this new drugs. Methods: This is a multicenter, real life, observational study. From January 2015 to December 2019 we recruited 98 patients with immunohistochemical(IHC) HR+/HER2-BC treated with CDK4-6 inhibitor plus HT. All patients were classified into intrinsic molecular subtypes based on PAM50 signature done centrally in diagnostic/metastatic biopsies. Results: The clinical and treatment characteristic are in table. In IHC studies all population were classified as luminalA (40%) and LuminalB (60%) but we found HER2 enriched patients (6%) defined by PAM50. The median PFS for all population was 14 months and median PFS for Luminal A subtype was 12 months and 15 months for Luminal B with no statistically significant differences between them. Conclusions: Based on the results obtained, the intrinsic molecular subtype defined by PAM50 does not appear to be associated with differences in PFS in our study group. However, a study with a larger number of patients would be necessary. Inhibitors of CDK4/6, have established a central role in the management of HR+/HER2-BC. There is a clear benefit in PFS and OS but we still don’t know which patients will benefit from this therapy and who will not while the side effects such chronic neutropenia, QTC prolongation and diarrhea could have a negative impact on their quality of life. Its mandatory to explore a good biomarker to direct therapy. [Table: see text]

Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study

The Breast ◽  
2019 ◽  
Vol 48 ◽  
pp. 7-16 ◽  
Author(s):  
M.E. Cazzaniga ◽  
G. Pinotti ◽  
E. Montagna ◽  
D. Amoroso ◽  
R. Berardi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Cancer Patients ◽  
Real World ◽  
Metronomic Chemotherapy ◽  
Advanced Breast ◽  
Breast Cancer Patients ◽  
The Real

scholarly journals BRCA status, treatment patterns and outcomes in HER2- advanced breast cancer (ABC): A multi-country real-world study

2019 ◽  
Vol 30 ◽  
pp. iii51-iii52
Author(s):  
A. Niyazov ◽  
R.G.W. Quek ◽  
K. Lewis ◽  
J. Kemp ◽  
A. Rider
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Real World ◽  
Treatment Patterns ◽  
Advanced Breast
Sign in / Sign up

Export Citation Format

Share Document